Clinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE)
1 other identifier
observational
70,000
1 country
1
Brief Summary
Primary central nervous system (CNS) tumors, the vast majority (\>90%) occurring in the brain and the remainder occurring in the meninges, spinal cord, and cranial nerves, showing an annual incidence of about 6-8 people per 100,000 population but its effects on health-care systems is out of proportion with incidence due to the substantial high rates of morbidity and mortality. Among which, glioma disease is the most common primary malignant CNS tumor, while the glioblastoma that showed the highest degree of malignancy and the worst prognosis accounts for 70-75%. The construction goal of this project is to construct a multivariate retrospective CNS tumor database (over 50,000 cases, including 10,000 glioma) integrating clinical information, preoperative magnetic resonance imaging examination and molecular pathological results, and a prospective glioma database (3,000 cases) integrating advanced magnetic resonance sequences and postoperative follow-up. It aims to form a standardized database integrating magnetic resonance imaging, pathological results, and clinical-prognostic information. Based on the construction of the above standardized database, the specifications for the acquisition of cranial magnetic resonance images, the image segmentation, tumor classification and labeling process, and the expert consensus on database construction and use management of CNS tumors were established. We aim to form a multimodal, large-capacity, high-quality, and rich medical imaging database that conforms to the characteristics of Chinese groups and clinical diagnosis and treatment norms. On this basis, the data are dynamically updated, in-depth mining, and the classification and grading standards of CNS tumor diseases, prognosis judgment criteria and treatment efficacy evaluation system are formulated, and providing comprehensive resources of retrospective data and prospective cohorts for large-scale reasearches, such as classification or treatment intervention predictions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2022
CompletedFirst Submitted
Initial submission to the registry
May 5, 2023
CompletedFirst Posted
Study publicly available on registry
May 16, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2030
March 9, 2026
March 1, 2026
9 years
May 5, 2023
March 5, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Establish standardized clinical-MRI-molecular markers database for CNS tumors
Collecting at least 50,000 retrospective data of CNS tumors patients, including preoperative brain MRI, clinical infromations, histopathology resuluts, and molecular markers, to establish a multi-modal clinical-MRI-molecular database
2022.06-2023.12
Establish prospective brain tumor cohort with multiomics information
Prospectively include at leaset 10,000 patients with brain space occupying lesions comfirmed by neuroimaging, recording their pre- and postoperative brain MRI, imaging diagnosis, histopathology or molecular pathology results, clinical intervention, treatment effect, and survival time.
2022.06.01-2030.12.31
Secondary Outcomes (1)
Accurately predicting the molecular and survival of glioma patients based on a deep learning model
2022.01-2024.12
Other Outcomes (1)
Establish a large-scale foundation model for brain tumors on MRI
2024.12-2026.12
Study Arms (2)
Retrospective database of CNS tumors included in the WHO classification (2021)
The subtypes of brain tumors were confirmed by the postoperative histopathology or molecular pathology
Prospective cohort of suspected CNS tumors
Intracranial mass lesion comfirmed by preoperative neuroimaging
Interventions
This study does not intervene in this process.
Eligibility Criteria
To reflect the daily practices, this study includes all patients with diffuse glioma at the beginning of the study.
You may qualify if:
- (1) a clear diagnosis of glioma based on pathological results;
- (2) The MRI sequence is complete and there are no obvious artifacts in the image;
- (3) The patient signs an informed consent form
You may not qualify if:
- (1) Suffering from other neurological diseases;
- (2) Prior to enrollment, surgery or biopsy, or a history of radiation therapy or chemotherapy;
- (3) Unable to complete clinical scoring and related laboratory tests, unable to complete follow-up;
- (4) Unable to tolerate MRI examination; Poor image quality, such as motion artifacts.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Yaou Liulead
Study Sites (1)
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100053, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yaou Liu, Doctor
Beijing Tiantan Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
May 5, 2023
First Posted
May 16, 2023
Study Start
January 1, 2022
Primary Completion (Estimated)
December 31, 2030
Study Completion (Estimated)
December 31, 2030
Last Updated
March 9, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- Within 3 years after the end of the trial.
- Access Criteria
- Neurosurgeon and radiologist who submitting an application to Prof. Liu.
Clinical and MR data can be shared.